Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Genelux Corporation Common Stock(GNLX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GNLX
09/25/2026: GNLX (1-star) is currently NOT-A-BUY. Pass it for now.
Genelux Corporation is a clinical-stage biotechnology company focused on developing its proprietary oncolytic virus platform, GL-ONC1, for treating solid tumors. The company has a specialized niche in viral immunotherapy, supported by two decades of research and development. Its primary growth opportunity lies in the potential for clinical trial success to lead to partnerships or licensing with larger pharmaceutical entities. However, investors face substantial risks, including the lack of current revenue, high cash burn, and the inherent uncertainty of clinical development processes. The stock may suit speculative growth investors with a high risk tolerance who are closely monitoring clinical trial data and company funding developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward speculative growth potential tied to clinical outcomes. |
| Momentum investor | Mixed fit | This is a volatile stock sensitive to clinical trial announcements and speculative trading patterns. |
| Value investor | Weak fit | The lack of revenue and earnings makes traditional valuation metrics like P/E inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | High volatility and the risks associated with clinical development are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical news and market sentiment. |
| Valuation risk | High | Valuation is speculative and heavily dependent on long-term clinical potential. |
| Competition risk (Oncology/Immunotherapy) | High | Large incumbents control standard-of-care, creating high barriers to market entry. |
| Business quality | Medium | The company holds specialized intellectual property but lacks commercial infrastructure. |
| Dividend income | Low / none | There is no expectation of income or capital return via dividends. |
| Execution risk | High | Success depends entirely on the outcome of complex and lengthy clinical trials. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -5.46% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.21M USD | Price to earnings Ratio - | 1Y Target Price 18.83 |
Price to earnings Ratio - | 1Y Target Price 18.83 | ||
Volume (30-day avg) 304.7K shares | Beta 0.56 | 52 Weeks Range 2.29 - 8.54 | Updated Date 09/25/2026 |
52 Weeks Range 2.29 - 8.54 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.86 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology R&D | Clinical trial development for GL-ONC1. | The company currently does not generate revenue; its value depends on the future success of its clinical pipeline. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 97.32M | Price to Sales(TTM) 14026.05 |
Enterprise Value 97.32M | Price to Sales(TTM) 14026.05 | ||
Enterprise Value to Revenue 12164.47 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 45.25M | Shares Floating 36.44M |
Shares Outstanding 45.25M | Shares Floating 36.44M | ||
Percent Insiders 12.87 | Percent Institutions 31.01 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquarters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.genelux.com |
Full time employees 25 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.